DOI: 10.36347/sajp.2022.v11i03.001

Pages: 41-45

The coronavirus infection caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be related with a wide range of disease and ranging from mild to life-threatening pneumonia. Patients with COVID-19 have higher susceptibility to fungal coinfections. Mucormycosis is a rare and-threatening fungal infection. Mucormycosis is more common in immunocompromised individuals, and patients with uncontrolled diabetes. COVID-19 associated mucormycosis usually developed 10-14 days after hospitalization. A high number of suspicion diagnosis and aggressive management is required to improve outcomes of the therapy. Awareness of warning symptoms and signs play an important role for the identification of the mucormycosis.